Tags : Nyvperia

Pfizer Receives the US FDA’s Approval for its Nyvepria (biosimilar,

Shots: The US FDA has approved Nyvepria (pegfilgrastim-apgf) to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer therapies associated with a clinically significant incidence of febrile neutropenia The approval is based on the comprehensive data package and totality of evidence demonstrating a high bio similarity […]Read More